Paclitaxel, bropirimine and linomide: effect on growth inhibition in a murine prostate cancer model by different growth regulatory mechanisms.
Paclitaxel, bropirimine and linomide therapy was evaluated in a murine prostate cancer model. All drugs were effective in impeding tumor growth but the mechanisms of action varied. Paclitaxel inhibited bcl-2 expression suggesting an apoptotic mechanism. Bropirimine, while inhibiting bcl-2 expression also significantly depressed tumor necrosis factor-alpha (TNF-alpha) expression. In the bropirimine treated group there was also a correlation between angiogenesis and cyclin D expression. Finally, linomide significantly decreased angiogenesis. Since the mechanism of action of these drugs differ, combining them at lower doses might maintain therapeutic efficacy while reducing toxicity.
Shaw
M
M
Division of Cellular Biology, Hektoen Institute for Medical Research, Chicago, USA.
Ratanawong
S
S
Chou
P
P
Ray
V
V
Mirochnik
Y
Y
Slobodskoy
L
L
Rubenstein
M
M
Guinan
P
P
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D003596:Cytosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D006912:Hydroxyquinolines / Q000494:pharmacology*; D007150:Immunohistochemistry; D008297:Male; D051379:Mice; D008954:Models, Biological; D017239:Paclitaxel / Q000494:pharmacology*; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D051381:Rats; D011916:Rats, Inbred F344
D000970:Antineoplastic Agents; D006912:Hydroxyquinolines; D019253:Proto-Oncogene Proteins c-bcl-2; C045282:roquinimex; D003596:Cytosine; C033560:bropirimine; D017239:Paclitaxel